Possible Collateral Estoppel in OxyContin Case Due to This Month’s Teva Decision

Purdue Pharma L.P. v. Epic Pharma, LLC

Case Number: 1:13-cv-00683-SHS (Dkt. 23)

Judge Stein, in light of his previously-issued Findings of Fact and Conclusions of Law in related matters (Dkt. 634) that held certain claims of U.S. Patents Nos. 7,674,799 (entitled “Oxycodone hydrochloride having less than 25 ppm 14–hydroxycodeinone”), 7,674,800 (same), 7,683,072 (same), and 7,776,314 (entitled “Abuse-proofed dosage system”) invalid, found plaintiffs to be collaterally estopped from arguing for these patent claims’ validity in the instant matter.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.